If these findings do have any relevance to medical practice in humans, it might therefore be that AMPK activators could be used to prevent or delay cancer in individuals who were at high risk of its development because of other genetic factors, analogous to the mice with the T-cell-specific knockout of PTEN (Figure 9). Here, PRKAA2 is linked to cancer.